CN215690913U

CN215690913U - Self-perfusion medicine elution balloon and self-perfusion medicine elution apparatus

Info

Publication number: CN215690913U
Application number: CN202121854053.1U
Authority: CN
Inventors: 刘禹辰
Original assignee: Jiangsu Changyida Medical Technology Co ltd; Shanghai Suchang Medical Technology Co ltd
Current assignee: Jiangsu Changyida Medical Technology Co ltd; Shanghai Suchang Medical Technology Co ltd
Priority date: 2021-08-10
Filing date: 2021-08-10
Publication date: 2022-02-01
Anticipated expiration: 2031-08-10

Abstract

The utility model relates to the field of medical instruments, in particular to a self-perfusion drug eluting balloon and a self-perfusion drug eluting instrument. The self-priming drug eluting device includes the self-priming drug eluting balloon and a delivery assembly. The self-perfusion drug eluting balloon does not block blood flow in the filling state, so that the situation of rapid physical rebound of the blood vessel caused by short adherence and support time is avoided.

Description

Self-perfusion medicine elution balloon and self-perfusion medicine elution apparatus

Technical Field

The utility model relates to the field of medical instruments, in particular to a self-perfusion drug eluting balloon and a self-perfusion drug eluting instrument.

Background

The intravascular angioplasty is a mature intravascular interventional technique applied clinically, has wide application in treating cardiovascular and cerebrovascular diseases (such as coronary heart disease, myocardial infarction, atherosclerosis, cerebral infarction, malignant tumor, cancer and the like), and is approved by both doctors and patients due to the characteristics of small wound, safety and effectiveness.

The specific implementation method is that under the guidance of medical imaging equipment, a catheter is inserted into a blood vessel through a percutaneous puncture technology, the dilator is guided to a focus through a guide wire, the dilator is expanded through external inflation or self-expansion, plaque is cracked under the action of pressure, the inner diameter of the blood vessel is recovered, the blood circulation is accelerated, and the medicine on the surface of the carrier is attached to the focus to achieve a relevant treatment effect. However, after angioplasty, the possibility of restenosis increases due to vascular endothelial injury, smooth muscle cell hyperproliferation, and post-operative restenosis. The main principle of the drug eluting balloon is that a layer of anti-cell proliferation drug is coated on the surface of the balloon, the balloon reaches a focus along a guide wire, and the drug on the surface is attached to a narrow part in a filling expansion mode, so that the effect of expanding a blood vessel and inhibiting the stenosis in the blood vessel is achieved.

Although the drug-coated balloon catheter has a certain positive effect on the treatment of restenosis, the following technical difficulties are found in the existing clinical practice process: 1. in the process that the saccule with the medicine sprayed on the surface enters the blood vessel, the medicine on the surface of the saccule can fall off due to friction with the inner wall of the blood vessel, so that the medicine can not be completely delivered to a diseased part by the medicine saccule; 2. the core idea of the drug eluting balloon technology is local drug delivery, so that the key is to evaluate an important technical index of the drug eluting balloon, namely, the coating, so that the key is to improve the firmness of the drug coating in the blood vessel while considering the release degree of the drug coating and the capability of the drug absorbed by the blood vessel; 3. in both the delivery and release phases, the drug coating is flushed away by the blood with more drug and very little drug acting locally. Although drug uptake can be increased locally by increasing the drug loading of the balloon coating, the large excess of drug flowing to the distal end of the vessel has a large negative impact on the health of the patient. 4. The drug eluting balloon has a blocking effect on blood vessels in the lesion expansion process, so that blood in the blood vessels is not circulated, the risk of ischemic necrosis of functional tissues at the downstream of the blood vessels is greatly increased, even if the risk is avoided by reducing the expansion time, the drug is not easily released from the balloon, and the curative effect is also greatly reduced.

SUMMERY OF THE UTILITY MODEL

In view of the above-mentioned shortcomings of the prior art, it is an object of the present invention to provide a self-priming drug eluting balloon and a self-priming drug eluting device, which are used to solve the problems of the prior art.

In order to achieve the above and other related objects, the present invention provides a self-priming drug eluting balloon, which includes a balloon body, wherein the balloon body extends axially and has two open ends, and a blood flow channel is disposed along the axial direction of the balloon body and is disposed on the wall of the balloon body.

Preferably, the blood flow channel is arranged inside the balloon wall of the balloon body.

Preferably, the balloon body comprises an outer balloon and an inner balloon arranged in the outer balloon, and the blood flow channel is arranged on the wall of the outer balloon.

The utility model also provides a self-perfusion drug elution apparatus, which comprises the self-perfusion drug elution balloon and a conveying assembly, wherein the conveying assembly comprises an outer tube and an inner tube, the inner tube penetrates through the balloon body through openings at two ends of the balloon body, the far end of the outer tube is sleeved with the near end of the inner tube, a gap is reserved between the outer tube and the inner tube at the sleeved position, and the inner cavity of the outer tube is communicated with the inner cavity of the balloon body through the gap.

As described above, the self-priming drug eluting balloon and the self-priming drug eluting apparatus of the present invention have the following beneficial effects:

1. because the surface of the outer balloon is coated with the functional drug coating and clings to the focus of the vessel wall in the drug release process, the drug loss caused by blood scouring in the motion transfer process of the balloon is greatly reduced, and meanwhile, the toxic and side effects of the lost drug on patients are also reduced to the greatest extent.

2. Because the self-filling medicine elution saccule does not block blood flow in the filling state, the situation that the blood vessel is physically rebounded fast due to short-time adherence and short supporting time is avoided.

3. The long-time adherence can ensure that the medicine is fully diffused into the lesion part, and the effective release rate of the medicine is improved while the clinical treatment effect is also improved.

4. The blood flowing all the time reduces the risk of ischemic necrosis of the downstream functional tissue of the blood vessel due to the non-flowing blood in the blood vessel.

In summary, the self-priming drug eluting balloon and self-priming drug eluting device of the present application have high transfer rate, high release, low toxicity and blood circulation.

Drawings

Fig. 1 is a schematic axial cross-sectional view of a self-priming drug eluting balloon of the present invention.

Fig. 2 is a schematic diagram showing a transverse cross-section of a self-priming drug eluting balloon of the present invention, the location and orientation of the cross-section being shown in phantom and by arrows in fig. 1.

Fig. 3 is an axial cross-sectional view of the self-priming drug-eluting balloon of the present invention after filling a blood vessel, wherein a represents the blood flow direction.

Fig. 4 is a transverse cross-sectional view of the self-priming drug-eluting balloon of the present invention after filling a blood vessel, the cross-sectional position and orientation being shown in phantom lines and arrows connecting the phantom lines in fig. 3.

Description of the element reference numerals

1 balloon body

11 outer balloon

12 inner balloon

2 blood flow channel

3 drug coating

4 outer tube

5 inner pipe

51 RX port

6 sacculus fills pressure release pipe

7 developing mark

71 first developing element

72 second developing element

8 vessel wall

Detailed Description

The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.

Please refer to fig. 1 to 4. It should be understood that the structures, ratios, sizes, and the like shown in the drawings and described in the specification are only used for matching with the disclosure of the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions under which the present invention can be implemented, so that the present invention has no technical significance, and any structural modification, ratio relationship change, or size adjustment should still fall within the scope of the present invention without affecting the efficacy and the achievable purpose of the present invention. In addition, the terms "upper", "lower", "left", "right", "middle" and "one" used in the present specification are for clarity of description, and are not intended to limit the scope of the present invention, and the relative relationship between the terms and the terms is not to be construed as a scope of the present invention.

The patent provides an optimization scheme of self-perfusion drug elution balloon, and a unique 'lotus seedpod' balloon structure is designed and a multi-layer functional coating is coated on the surface of the balloon, so that the drug balloon is expanded in blood vessels and has high transfer rate, high release performance, low toxicity and blood circulation.

As shown in fig. 1 and 2, the present invention provides a self-perfusion drug elution balloon, which includes a balloon body 1, wherein the balloon body 1 extends axially and has two open ends, a blood flow channel 2 is arranged along the axial direction of the balloon body 1, and the blood flow channel 2 is arranged on the wall of the balloon body 1.

The two end openings of the balloon body 1 are respectively called a proximal end opening and a distal end opening. In this application, the term "proximal" generally refers to the end of the corresponding component that is near the operator, e.g., the left end in fig. 1; "distal end" means the end of the corresponding part remote from the operator, e.g. the right end in fig. 1.

Specifically, the blood flow channel 2 is arranged inside the balloon wall of the balloon body 1. The balloon wall of the balloon body 1 comprises an outer surface and an inner surface, i.e. the blood flow channel 2 is arranged between the outer surface and the inner surface of the balloon body 1. The balloon wall thickness of the balloon body 1 is larger than the diameter of the blood flow channel 2.

At least two blood channels 2 are provided.

In one embodiment, the blood channels 2 are symmetrically distributed around the central axis.

In a preferred embodiment, the balloon body 1 comprises an outer balloon 11 and an inner balloon 12 disposed therein, and the blood flow channel 2 is disposed on the wall of the outer balloon 11.

In a preferred embodiment, the blood flow channel 2 is disposed inside the balloon wall of the outer balloon 11. The balloon wall of the outer balloon 11 comprises an outer surface and an inner surface, i.e. the blood flow channel 2 is arranged between the outer surface and the inner surface of the outer balloon 11. The outer surface and the inner surface of the outer balloon 11 except the blood flow channel 2 are all solid structures. In one embodiment, the outer balloon 11 has a wall thickness (i.e., the thickness between the outer surface and the inner surface) of 0.02-0.2 mm.

The diameter of the blood flow channel 2 is smaller than the wall thickness of the outer balloon 11. In one embodiment, the blood flow channel 2 has a diameter of 0.01 to 0.1 mm.

The inner balloon 12 is a hollow structure.

The outer balloon 11 and the inner balloon 12 are both compliant balloons. The compliance is the change of the shape or volume of the balloon when the balloon is inflated by adding one atmosphere, and is an index of the stretching capacity of the balloon. The diameter of the non-compliant balloon increases very little before the rupture point is reached. Therefore, the balloon with the proper size matched with the blood vessel can be selected to almost ensure that the blood vessel can not be broken (transmural tearing) when the blood vessel is expanded and formed.

And the outer surface of the outer balloon 11 is also provided with a drug coating 3. The drug is selected from anti-cell migration drug, anti-cell mitosis drug, anti-proliferation drug, hydrophilic material, and amphiphilic material.

The anti-cell migration drug, anti-cell mitotic drug, or anti-proliferative drug is selected from one or more of rapamycin, paclitaxel derivatives, rapamycin derivatives, paclitaxel analogs, rapamycin analogs, inhibitory RNA, inhibitory DNA, steroids, or complement inhibitors.

The hydrophilic material is, for example, one of polyvinylpyrrolidone, polyethylene oxide, polyacrylamide, polyacrylic acid, polyether and its derivatives, urea, polyurethane urea, polyethylene glycol, polypropylene glycol, iopromide, or a composite thereof.

The amphiphilic material is selected from any one or more of a surfactant, fatty acid, amino acid, phospholipid or phospholipid derivative. Such as sodium dodecyl sulfate, sodium dodecyl benzene sulfonate, stearic acid, lauric acid, tetradecadienoic acid, caprylic acid, glycine, glutamic acid, sarcosine, alanine, 1, 2-bis (eicosanoyl) -sn-glycero-3-phosphocholine, 1, 2-dianeoyl-sn-glycero-3-phosphocholine, 1, 2-bis-erucyl-sn-glycero-3-phosphocholine, 1, 2-bis (docosahexenoyl) -sn-glycero-3-phosphocholine, 1, 2-heneicosenoyl-sn-glycero-3-phosphocholine or 1, 2-didecanonic-sn-glycero-3-phosphocholine or a complex thereof.

The drug coating 3 may be one layer or a plurality of layers. The self-perfusion drug elution balloon coated with one or more drug coatings 3 is divided into a plurality of flaps and then folded and curled to form a flap, the inner balloon and the outer balloon are folded after drying, so that the drug is stored in the flap, and then the inner balloon and the outer balloon are sleeved with a protective sleeve, so that the shapes of the drug and the inner balloon and the outer balloon are stored.

The outer balloon 11 or the inner balloon 12 is selected from elastic materials. The elastic material can ensure that the outer layer saccule 11 or the inner layer saccule 12 can be folded in the conveying process or during storage, and can be expanded under the action of air pressure after being conveyed to a target position. The material of the elastic outer layer balloon 11 or the inner layer balloon 12 is selected from the elastomer materials of polyvinyl chloride, polyethylene terephthalate, nylon, polyisoprene, polystyrene copolymer, polysiloxane or polyurethane.

The shape of the outer balloon 11 or the inner balloon 12 is selected from a spindle shape, a cylindrical shape or a spherical shape. The two ends of the outer balloon 11 or the inner balloon 12 are hollowed out, so that the outer tube 4 and/or the inner tube 5 can penetrate through the hollowed-out parts.

Rated air pressure is applied to the self-filling medicine elution balloon, and when the outer balloon 11 is full, the blood flow channel 2 in the outer balloon 11 can play a role in treating without blocking blood flow.

As shown in fig. 1 and 2, the present invention further provides a self-perfusion drug elution apparatus, which includes the self-perfusion drug elution balloon and a conveying assembly, wherein the conveying assembly includes an outer tube 4 and an inner tube 5, the inner tube 5 penetrates through the balloon body 1 through openings at two ends of the balloon body 1, a distal end of the outer tube 4 is sleeved with a proximal end of the inner tube 5, a gap is left between the outer tube 4 and the inner tube 5 at the sleeved position, and an inner cavity of the outer tube 4 is communicated with an inner cavity of the balloon body 1 through the gap.

As shown in fig. 2, the outer tube 4 and the inner tube 5 are of a coaxial dual-lumen structure.

In one embodiment, both the outer balloon 11 and the inner balloon 12 are wrapped around at least a portion of the inner tube 5. The proximal openings of the outer balloon 11 and the inner balloon 12 are both connected to the outer tube 4 in a sealing manner, and the distal openings of the outer balloon 11 and the inner balloon 12 are both connected to the inner tube 5 in a sealing manner. In one embodiment, the sealed connection is a sealed fixed connection. The fixed connection is selected from welding or gluing.

The far end of the outer tube 4 penetrates through the near end opening of the balloon body 1, and the far end port of the outer tube 4 is positioned in the inner cavity of the balloon body 1, or the far end port of the outer tube 4 is communicated with the near end opening of the balloon body 1. The specific arrangement may be that the outer tube 4 may extend from the outside of the infused drug eluting balloon to one end of the infused drug eluting balloon, or from the outside of the infused drug eluting balloon to the inside of the inner balloon 12 through one end of the infused drug eluting balloon. The outer tube 4 does not penetrate the self-priming drug eluting balloon.

Preferably, the inner surface of the outer balloon 11 is connected to the outer tube 4 and/or the inner tube 5. To ensure that the blood flow channel 2 can expand to allow blood to pass therethrough.

The outer tube 4 has an inner diameter slightly larger than the outer diameter of the inner tube 5. A certain gap is formed between the inner tube and the outer tube, the inner cavity of the outer tube 4 is communicated with the inner cavity of the balloon body 1 through the gap, namely the gap can be used for providing a channel for contrast medium or normal saline to expand the outer balloon 11 or the inner balloon 12. The inner diameter of the outer pipe 4 and the inner diameter of the inner pipe 5 can be adjusted according to requirements through different dies. The material of the outer tube 4 is selected from polyurethane elastomer (TPU), nylon or block polyether amide resin (PEBAX). The material of the inner tube 5 is nylon or PEBAX.

In one embodiment, the delivery assembly further comprises a balloon inflation and deflation catheter 6, the balloon inflation and deflation catheter 6 being in communication with the outer tube 4. The connection mode of the balloon pressure-relief catheter 6 and the outer tube 4 is welding or bonding. The balloon pressure-relief catheter 6 is made of plastic. Examples of plastics are polycarbonates, polyurethanes, acrylonitrile-butadiene-styrene plastomers, polyamides, etc.

The proximal end port of the inner tube 5 penetrates the wall of the outer tube 4 to form an RX port 51 communicated with the outside. The RX port 51 may be used for the self-priming drug eluting balloon to pass over a delivery guidewire when delivered. The RX port 51 is connected to the outer tube 4 by welding or bonding.

The self-priming drug eluting device further comprises a developing mark 7, wherein the developing mark 7 is a developing element arranged on the outer surface of the inner tube 5, or the inner tube 5 is formed with the developing mark 7. Preferably, the development mark 7 is a development element arranged on an inner tube section inside the inner balloon 12, or the development mark 7 is formed on the inner tube section inside the inner balloon 12. The developing member may be a metal ring. The developing member is provided in plurality. The developing members are, for example, two, respectively, a first developing member 71 and a second developing member 72. Both visualization elements are located on the inner tube section inside the inner balloon 12. The inner tube section inside the inner balloon 12 may be made of a material having a developing function to form the developing mark 7, or by coating a developer or winding a developing wire or the like on the inner tube section inside the inner balloon 12. The developing wire is made of gold, platinum, PtW alloy or PtIr alloy.

The self-priming drug eluting device of the present application may be used in conjunction with delivery systems of the prior art (including guidewires, etc. in the delivery system).

The self-priming drug elution apparatus of the present application is used as follows:

as shown in fig. 3, firstly, the blood vessel lesion site is pretreated, then a guide wire is threaded into the inner tube 5 through the RX port 51, the self-priming drug eluting balloon is placed in the body, under the irradiation of X-rays and the guidance of the guide wire, whether the self-priming drug eluting balloon reaches the lesion site is determined according to the positions of the first developing element 71 and the second developing element 72 in the inner balloon 12, when the lesion site is located between the first developing element 71 and the second developing element 72, a contrast medium or normal saline is injected into the inner balloon 12 through the balloon pressure charging and discharging catheter 6, the inner balloon 12 is expanded to a rated pressure (as shown in fig. 3 and 4), the outer balloon 11 is also forced to expand while the inner balloon 12 is expanded, the blood flow channel 2 in the outer balloon 11 is completely expanded, the blood flow can pass through the blood flow channel 2, normal body fluid circulation is performed, and the drug coating 3 on the surface of the outer balloon 11 is in the process of self-priming drug eluting balloon and inflated expansion and the balloon The narrow part of the vessel wall 8 is attached, so that the medicinal components can treat the narrow pathological part of the vessel (as shown in figure 3). After the medicine is fully transferred to the blood vessel, negative pressure pumping operation is carried out on the self-perfusion medicine elution balloon to enable the self-perfusion medicine elution balloon to be in an unfilled state, then the self-perfusion medicine elution balloon is pumped outwards along the guide wire, due to the design of the blood flow channel 2, the administration time is not limited, re-expansion treatment can be carried out according to the retraction condition of the blood vessel after administration is finished, and secondary administration is carried out if necessary.

To sum up, the self-priming medicine elution sacculus of this application and self-priming medicine elution apparatus are because have and are located outer sacculus inside, and outer sacculus is the blood runner of integrative "lotus seedpod formula", when filling pressure release pipe and aerifing to self-priming medicine elution sacculus through the sacculus, the inside blood runner of sacculus can strut along with the sacculus expansion, when playing and dosing for pathological change department, do not hinder blood circulation again, therefore its administration time can be confirmed according to the vasodilatation condition and the blood vessel condition of retracting. Compared with the existing self-perfusion saccule which is opened at the position of the catheter to facilitate the blood circulation in the same type, the 'lotus seedpod' blood flow channel of the self-perfusion saccule is symmetrically distributed, and the blood circulation and the blood pressure stability of the self-perfusion saccule are better. Therefore, the utility model effectively overcomes various defects in the prior art and has high industrial utilization value.

The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the utility model. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.

Claims

1. The utility model provides a from pouring into medicine elution sacculus, its characterized in that, including sacculus body (1) from pouring into medicine elution sacculus, sacculus body (1) axial extension and both ends opening are followed the axial of sacculus body (1) is equipped with blood runner (2), blood runner (2) are located on the wall of sacculus body (1).

2. A self-priming drug elution balloon according to claim 1, wherein the blood flow channel (2) is provided inside the balloon wall of the balloon body (1).

3. A self-priming drug elution balloon according to claim 1, wherein there are at least two blood flow channels (2).

4. A self-priming drug elution balloon according to claim 3, wherein the blood flow channels (2) are symmetrically distributed around the central axis.

5. A self-priming drug elution balloon according to claim 1, wherein the balloon body (1) comprises an outer balloon (11) and an inner balloon (12) arranged therein, the blood flow channel (2) being arranged on the wall of the outer balloon (11).

6. A self-priming drug elution balloon according to claim 5, wherein the blood flow channel (2) is provided inside the balloon wall of the outer balloon (11).

7. A self-priming drug eluting balloon according to claim 5, wherein the outer balloon (11) is further provided with a drug coating (3) on its outer surface.

8. A self-perfusion drug elution apparatus, which comprises the self-perfusion drug elution balloon and a conveying assembly according to any one of claims 1 to 7, wherein the conveying assembly comprises an outer tube (4) and an inner tube (5), the inner tube (5) penetrates through the balloon body (1) through openings at two ends of the balloon body (1), the far end of the outer tube (4) is sleeved with the near end of the inner tube (5), a gap is reserved between the outer tube (4) and the inner tube (5) at the sleeved position, and the inner cavity of the outer tube (4) is communicated with the inner cavity of the balloon body (1) through the gap.

9. A self-irrigating drug eluting device according to claim 8, wherein the distal end of the outer tube (4) penetrates the proximal opening of the balloon body (1) and the distal end port of the outer tube (4) is located in the balloon body (1) lumen or the distal end port of the outer tube (4) is in communication with the proximal opening of the balloon body (1).

10. A self-priming drug elution device according to claim 8, wherein the proximal openings of the outer balloon (11) and the inner balloon (12) are both sealingly connected to the outer tube (4), and the distal openings of the outer balloon (11) and the inner balloon (12) are both sealingly connected to the inner tube (5).

11. A self-priming drug elution device according to claim 8, wherein the inner surface of the outer balloon (11) is connected to the outer tube (4) and/or the inner tube (5).

12. A self-priming drug elution instrument according to claim 8, wherein the delivery assembly further comprises a balloon inflation and deflation catheter (6), the balloon inflation and deflation catheter (6) being in communication with the outer tube (4).

13. A self-priming drug elution device according to claim 8, wherein the proximal port of the inner tube (5) penetrates the wall of the outer tube (4) forming an RX port (51) communicating with the outside; and/or, the self-priming drug elution apparatus further comprises a development mark (7), wherein the development mark (7) is a development element arranged on the outer surface of the inner tube (5), or the inner tube (5) is formed with the development mark (7).